$SCAI (Surgical Care Affiliates, Inc.)

$SCAI {{ '2016-09-01T13:19:09+0000' | timeago}} • Announcement

$SCAI said that along with Virtua Health, a New Jersey-based healthcare provider, the company has been chosen to partner with Bergen-Passaic Cataract Laser and Surgery Center, an ophthalmic focused facility in New Jersey.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$THC {{ '2018-01-05T17:28:17+0000' | timeago}} • Announcement

$THC and St. Luke’s Hospital, an independent, non-profit healthcare provider, have entered into a definitive agreement for St. Luke’s to purchase Des Peres Hospital as well as Tenet-owned physician practices and other hospital-affiliated operations in St. Louis. The transaction is expected to be completed early in 2018.

$THC {{ '2018-01-04T22:16:28+0000' | timeago}} • Announcement

$THC and Baylor Scott & White Health plan to restructure their JV arrangements for three North Texas hospitals by spring of 2018. Baylor Scott & White will acquire $THC’s minority interest in Baylor Scott & White - Centennial and Baylor Scott & White - Lake Pointe. Baylor Scott & White - Sunnyvale will become part of Texas Health Ventures Group.

$AHS {{ '2018-01-04T15:49:10+0000' | timeago}} • Announcement

Peak Health Solutions, an $AHS company, appointed Brad Hill as its president. Hill brings to AMN over 25 years of healthcare leadership experience, primarily in revenue cycle technology and services for both payers and providers. He was most recently the chief revenue officer at RemitDATA, a healthcare technology company.

$ABC {{ '2018-01-03T14:03:33+0000' | timeago}} • Announcement

$ABC completed the acquisition of H. D. Smith, the largest independent wholesaler in the U.S., for $815MM in cash. The acquisition is designed to enhance and expand the company's strategic scale, strengthen its support to community pharmacy and drive long-term, durable value.

$MYGN {{ '2018-01-03T13:32:07+0000' | timeago}} • Announcement

$MYGN said $AZN will use its myChoice HRD Plus test in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza & Avastin. Under the agreement, $MYGN will use its myChoice Plus test to evaluate patients enrolled in an ongoing Phase III trial. Financial terms were not disclosed.

$THC {{ '2017-12-26T17:43:20+0000' | timeago}} • Announcement

$THC and Baylor Scott & White Health have agreed to sell Baylor Scott & White Medical Center - White Rock, a 218-bed hospital located in Dallas, Texas, to Pipeline Health, LLC. The hospital is part of a JV partnership with Baylor Scott & White Health, in which $THC is the minority owner. The transaction is expected to be completed in 1Q18.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$THC {{ '2017-12-19T13:06:16+0000' | timeago}} • Announcement

For FY18, $THC expects its net income to be in the range of $65-70MM with EPS of about $0.63-0.68. Adj. EPS is expected to be about $1.07-1.36. Net operating revenue is expected to be about $17.8-18.2Bil.

$THC {{ '2017-12-19T13:04:06+0000' | timeago}} • Announcement

$THC said it would explore a sale of its subsidiary Conifer. The company expects to make a decision regarding the sale during the first half of 2018. Goldman, Sachs & Co. LLC as its financial advisor and Kirkland & Ellis LLP are the legal advisor.

$THC {{ '2017-12-19T13:00:29+0000' | timeago}} • Announcement

$THC has increased the size of its previously announced cost reduction initiative by  $100MM. The company now expects to achieve $200MM of annualized savings by the end of 2018. $THC has also started a process to refresh the composition of its BoD. The board currently consists of 12 directors.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$ANTM {{ '2017-12-11T14:59:25+0000' | timeago}} • Infographic

At a time when the US health insurance sector stares at a rise in premium prices, amid the government’s move to repeal the Individual Mandate clause, an analysis shows that major players in the sector registered consistent revenue growth over the past ten years. $ANTM $UNH $AET $HUM $CI

$AGN {{ '2017-12-05T18:08:04+0000' | timeago}} • Announcement

Revance Therapeutics reported positive data for RT002, an injectable drug which would treat glabellar or frown lines. With positive results from the two Phase 3 trials, $AGN's rival plans to complete the third Phase 3 trial in 2H18 and file for FDA approval in 1H19, and introduce the competitive drug for Allergan's Botox in the U.S. in 2020.

$CVS {{ '2017-12-04T21:29:13+0000' | timeago}} • Announcement

$CVS has agreed to acquire $AET for appox. $207 per share or approx. $69Bil. Including the assumption of $AET debt, the total value of the deal is $77Bil. The transaction is expected to close in the second half of 2018.

Recent Transcripts

PDCO (Patterson Companies, Inc.)
Tuesday, November 21 2017 - 3:00pm
ENTA (Enanta Pharmaceuticals, Inc.)
Monday, November 20 2017 - 9:30pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
RDNT (RadNet, Inc.)
Thursday, November 9 2017 - 3:30pm
SGRY (Surgery Partners, Inc.)
Thursday, November 9 2017 - 1:30pm
EGLT (Egalet Corporation)
Wednesday, November 8 2017 - 1:30pm
MSON (Misonix, Inc.)
Tuesday, November 7 2017 - 9:30pm
ELGX (Endologix Inc.)
Tuesday, November 7 2017 - 9:30pm
THC (Tenet Healthcare Corp.)
Tuesday, November 7 2017 - 3:00pm
ZIOP (ZIOPHARM Oncology, Inc.)
Monday, November 6 2017 - 9:30pm
ECYT (Endocyte, Inc.)
Monday, November 6 2017 - 9:30pm
VCYT (Veracyte, Inc.)
Monday, November 6 2017 - 9:30pm
ABC (AmerisourceBergen Corporation)
Thursday, November 2 2017 - 12:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
EVHC (Envision Healthcare Holdings, Inc.)
Wednesday, November 1 2017 - 12:30pm
HCA (HCA Holdings, Inc.)
Tuesday, October 31 2017 - 2:00pm
AET (Aetna Inc.)
Tuesday, October 31 2017 - 12:30pm
PDCO (Patterson Companies, Inc.)
Thursday, August 24 2017 - 2:00pm
MSON (Misonix, Inc.)
Tuesday, August 22 2017 - 8:30pm
EGLT (Egalet Corporation)
Wednesday, August 9 2017 - 8:30pm

AlphaGraphics you may like